<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="abs0005">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="lis0005">
   <list-item id="lsti0005">
    <label>•</label>
    <p id="par0005">
     <italic>Japanese encephalitis virus</italic> (JEV) remains a leading cause of neurological infection in Asia.
    </p>
   </list-item>
   <list-item id="lsti0010">
    <label>•</label>
    <p id="par0010">A systematic review identified 20,212 published human cases of laboratory-confirmed JEV infections from 205 studies.</p>
   </list-item>
   <list-item id="lsti0015">
    <label>•</label>
    <p id="par0015">15,167 (75%) of cases were confirmed with the lowest confidence diagnostic test, i.e., level 3 or 4, or level 4.</p>
   </list-item>
   <list-item id="lsti0020">
    <label>•</label>
    <p id="par0020">Only 109 (53%) of the studies reported contemporaneous testing for dengue-specific antibodies.</p>
   </list-item>
   <list-item id="lsti0025">
    <label>•</label>
    <p id="par0025">A fundamental pre-requisite for the control of JE is lacking — that of a simple and specific diagnostic procedure that can be adapted for point-of-care tests and readily used throughout JE endemic regions of the world.</p>
   </list-item>
  </list>
 </p>
</abstract>
